Proactive Investors - Run By Investors For Investors

Breakfast News - AIM Breakfast : Creo Medical Group PLC, Frontier Developments, Green & Smart, James Latham, Milestone Group PLC, Redx Pharma Plc, Tandem Group plc, Universe Group plc, Velocys

Breakfast News - AIM Breakfast : Creo Medical Group PLC, Frontier Developments, Green & Smart, James Latham, Milestone Group PLC, Redx Pharma Plc, Tandem Group plc, Universe Group plc, Velocys

What’s cooking in the IPO kitchen?


GYG—Intention to float by the superyacht painting, supply and maintenance company. Due 5 July. Raising £6.9m new plus vendor sale of £21.5m at 100p. Mkt Cap c. £47m.  Revenue of €54.6m in FY16 and adjusted EBITDA of €6.7m.

Greencoat Renewables  - Schedule 1. Targeting a portfolio of operating renewable electricity generation assets, initially investing in wind generation assets in Ireland.  Offer TBC. Due Mid July.

FFI Holdings— Specialist in the provision of completion contracts to the entertainment industry for films, television, mini-series and streaming product. Offer TBA. Expected 30 June.

QUIZ— Omni-channel fast fashion womenswear Company intention to float. Due July 2017.  Offer TBA

Ethernity Networks—Schedule 1 from Israeli based specialist in data processing technology used in high end carrier ethernet applications across the telecom, mobile, security and data centre markets. Expected late June. Offer TBA.

Jangada Mines—Sch 1  advanced stage PGM exploration project containing what the Directors understand to be the largest PGM resource, and only pre-development PGM project, in South America.  Offer TBA. Expected late June.

Phoenix Global Mining— US Brown field copper play. Expected late June. Offer TBA

Touchstone Exploration— Oil E&P company active in the Republic of Trinidad and Tobago.  Interests of approximately 90k gross acres. Production c. 1.3k boepd. Raising £1.5m. Expected mkt cap £7.5m - 26 June.

I3 Energy –Schedule 1. Independent oil and gas company with assets and operations in the UK.  Offer TBC, 7 June admission.

Verditek— Schedule 1 update. On Admission, the Company's subsidiaries will be involved in advanced solar photovoltaic, filtration and absorption technologies specialising in providing environmental services. Issue price 10p.  Admission late June

Tiso Blackstar Group—Schedule 1 update. Media, entertainment and marketing solutions group/ £160m mkt cap. Admission only. Postponed.

Main Market Standard Listing

Rockpool Acquisitions—Northern Ireland based Company seeking  strong NI acquisition with an international outlook. Raising £1.5m at 10p. Due 5 July.

Main Market Premium Listing

Residential Secure  Income -  social housing REIT  raising up to £300m Admission due c.12 July.

ScotGems—Admission due 26 June. Seeking £50-£100m.  To investing in a diversified portfolio of Small Cap Companies listed on global stock markets

DP Eurasia—Intention to float from the  exclusive master franchisee of the Domino's Pizza brand in Turkey, Russia, Azerbaijan and Georgia . £20m primary raise plus a partial vendor sale.

AIB—Intention to float from  AIB, Ireland's leading retail and commercial bank. The Minister for Finance intends to sell approximately 25% of the Ordinary Shares of AIB. Valuation range €10.6-€13.3bn. Admission end June.

Curzon Energy—Report on Proactive Investors of intended LSE float this year  with acquisition of  coal bed methane assets in Oregon. Looking to raise £3m plus.

NLB Group—financial and banking institution based in Slovenia, with a network of 356 branches. Seeking Ljubliana Stock Exchange listing with GDRs on the LSE. Expected mid June.

Kuwait Energy— $150m raise plus vendor offer. Admission due June.  2p reserves 810.0 mmboe

Main Market Specialist Funds

Supermarket Income REIT– Up to £200m raise to acquire a diversified portfolio of supermarket real estate assets in the UK, providing long-term RPI-linked income. Due 21 July.   

Breakfast buffet

Velocys (LON:VLS) 48p £70.36m

AGM Statement from the Company at the forefront of smaller scale gas-to-liquids . "2016 was a busy year of change for Velocys. We invested significant effort into the commissioning and start-up of ENVIA Oklahoma, we identified our new growth strategy and have made considerable progress with its implementation. Internally we have driven greater simplicity and focus on what we do and we believe we have created the required platform to deliver future shareholder value.” "Our new strategy is for Velocys to be at the heart of building plants that convert woody biomass to high specification renewable diesel and jet fuel for the US market, our primary focus market.”

Green & Smart Holdings (LON:GSH) 9.38p £27.29m

The renewable energy Company generating power from biogas captured through the treatment of palm oil mill effluent in Malaysia, is pleased to announce the completion of the commissioning and interconnection works for its second fully-owned biogas power plant, the 2.0MW Malpom plant located in Nibong Tebal, Penang. Green & Smart is currently awaiting receipt of a certificate of initial operation date ("IOD"). The Group anticipates testing to be completed by the end of July 2017 when the plant will become fully operational at headline capacity. Shortly thereafter, the Group expects to receive the formal certificate of commercial operation date ("COD"), which will allow the Group to sell power to the local utility the full tariff rate.  HYMar17 results also today, rev+18% to RM25.8m, PBT down to RM3.8m from RM4.8m.

Electrical Geodesics (LON:EDI) 100p £27.53m

Recommended cash offer for the neurodiagnostic medical technology Company for a cash consideration of £29m (105.4p/share), a premium of approximately 36 percent to the closing price of £0.775 (77.5p) on 20 June 2017.  The Buyer is Philips, a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care.

Milestone Group* (LON:MSG) 0.13p £1.62m

The provider of digital media, technology and social impact solutions announces that Black Cactus Holdings, its joint venture partner in Nexstar, a subsidiary of Milestone, has launched a KYC (Know your customer) and AML (Anti Money Laundering) platform.

The new platform is part of a fintech solution designed to be used by those organisations involved in banking, gaming, insurance and card programmes amongst others. The platform ties into a number of major global databases to carry out background checks on both individuals and Corporates, these include criminal records, financial & personal history, sex offender registries, employment and payroll services databases, insurance and all other KYC and AML requirements.

Frontier Developments (LON:FDEV) 419p £142.93m

FYMay17 trading update  from the independent creator of video games. Good trading performance has continued since the last trading update on 19 April 2017. The Company expects to report revenue for the financial year ending 31 May 2017 of approximately £37.3 million, slightly ahead of previous guidance and a 75% increase over the prior year (FY16: £21.4 million). Operating profit margin for FY17 is expected to be towards the top of the 15-20% guidance range. The Company expects to report an operating profit (as calculated under IFRS) of at least £7.2 million, which is a 500% increase over the £1.2 million reported for the prior year. 

Universe Group (LON:UNG) 11.25p £26.05m

AGM Statement from the developer and supplier of point of sale, payment and on-line loyalty systems. "Trading in the first half of 2017 has been in line with management expectations. The Group is currently implementing new installations for recently-won contracts and therefore, like last year, the trading performance for the full year will be weighted towards the second half.” FYDec17E rev £21.98m, PBT £2.53m.

Tandem Group (LON:TND) 135p £6.64m

AGM Statement. "For the 24 week period to 16 June 2017 revenue was approximately 5.5% ahead of the comparative period last year. In our sports, leisure and toys businesses revenue was ahead of the prior year, driven by strong growth from both licensed and own brands.”  “Although revenue from our bicycles and mobility businesses was behind the prior period, following the restructuring exercise undertaken in the fourth quarter of last year, we are pleased to report that we have transformed the loss making bicycle business into profit.  We anticipate that we will be able to maintain profitability for the full year.” Sterling pressuring margins but order book +35%.  We could see no forecasts.

James Latham (LON:LTHM) 852.5p £167.4m

FYMar17 results  from the  timber and panel products distributor. Group revenue for the financial year to 31 March 2017 was £198.8m, 6.9% up on last year's £185.9m. The operating profit was £14.2m, up £1.0m from £13.2m. Final div of 10.85p vs 10.3p. This year like for like revenue, both in panels and timber, is 3% higher for April and May than the corresponding period last year which had two more working days. However the gross margin is still under pressure. Cash of £17.2m. NAV £73.3m. We could see no forecasts.

Redx Pharma (LON:REDX) In administration

The drug discovery and development company, is today providing an update on developments since the announcement of its suspension and appointment of Administrators. The Joint Administrators are working with the Company's advisers on proposals to rescue Redx and return the Company to the control of its directors, with the intention of lifting the suspension and restoring trading in the ordinary shares.  Discussions regarding these proposals are at a relatively early stage and there can be no guarantee that these will be concluded successfully in the short term.

Creo Medical (LON:CREO) 80p £63.36m

The medical device Company focused on the emerging field of surgical endoscopy announced the first clinical use of the Company's Speedboat device. The first patient with a large pre-cancerous lesion in the gastrointestinal (GI) tract was treated using Creo's Speedboat device powered by Creo's CROMA electrosurgery advanced energy platform.  The patient was treated by Professor Brian Saunders at St. Mark's Hospital in London, United Kingdom. The Speedboat device harnesses the precise cut and coagulation capability of CROMA to remove early cancerous and pre-cancerous lesions in the bowel.

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use